Screening for Cystic Fibrosis improves Nutritional status and Pulmonary Outcomes of newborn babies

Written By :  Dr. Shravani Dali
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2022-08-24 14:30 GMT   |   Update On 2022-08-24 14:31 GMT
Advertisement

Newborn Screening for Cystic Fibrosis improves their Nutritional status and Pulmonary Outcomes according to a recent study published in the JAMA Pediatrics

Newborn screening (NBS) for cystic fibrosis (CF) has been universal in the US since 2010, but its association with clinical outcomes is unclear.

A study was conducted to describe the real-world effectiveness of Newborn screening programs for cystic fibrosis in the US on outcomes up to age 10 years.

This was a retrospective cohort study using cystic fibrosis Foundation Patient Registry data from January 1, 2000, to December 31, 2018. The staggered implementation of Newborn screening programs by state was used to compare longitudinal outcomes among children in the same birth cohort born before vs after the implementation of Newborn screening for cystic fibrosis in their state of birth. Participants included children with an established diagnosis of cystic fibrosis born between January 1, 2000, to December 31, 2018, in any of the 44 states that implemented Newborn screening for CF between 2003 and 2010. Data were analyzed from October 5, 2020, to April 22, 2022.

Results of the study are:

  • A total of 9571 participants (4713 female participants [49.2%]) were eligible for inclusion, with 4510 (47.1%) in the pre- Newborn screening cohort.
  • Newborn screening was associated with higher weight and height percentiles in the first year of life, but these differences decreased with age.
  • There was no association between Newborn screening and FEV1 at age 6 years, but the percent-predicted FEV1 did increase more rapidly with age in the post-NBS cohort.
  • Newborn screening was associated with older age at chronic P aeruginosa infection but not initial P aeruginosa infection

Thus, Newborn screening for cystic fibrosis in the US was associated with improved nutritional status up to age 10 years, a more rapid increase in lung function, and delayed chronic P aeruginosa infection. In the future, as highly effective modulator therapies become available for infants with cystic fibrosis, Newborn screening will allow for presymptomatic initiation of these disease-modifying therapies before irreversible organ damage.

Reference:

Rosenfeld M, Ostrenga J, Cromwell EA, et al. Real-world Associations of US Cystic Fibrosis Newborn Screening Programs With Nutritional and Pulmonary Outcomes. JAMA Pediatr. Published online August 01, 2022. doi:10.1001/jamapediatrics.2022.2674

Tags:    
Article Source : JAMA Pediatrics

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News